Endovascular embolization stops nosebleeds
A minimally invasive technique can successfully stop recurrent nosebleeds in patients who are prone to them, according to a radiologist's study published in the Journal of NeuroInterventional Surgery.
A minimally invasive technique can successfully stop recurrent nosebleeds in patients who are prone to them, according to a radiologist's study published in the Journal of NeuroInterventional Surgery.
Nosebleeds can be particularly troubling for patients who have had nasal surgery or are taking blood thinners, aspirin, ibuprofen, or blood pressure drugs. In around 6% of cases, recurrent nosebleeds require nasal packing, heat cauterization, or invasive surgery to curb recurrence.
After endovascular embolization using platinum fiber coils, 19 of 20 patients had no further rebleeding, and only one patient had transient facial pain (J NeuroIntervent Surg 2010;2:171-175).
The technique uses a fine guidewire or catheter to insert detachable platinum coils. They expand into a predetermined shape to slow or block the flow of blood.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
